The devaluation of the French franc at the start of 1994 and its consequences for the accessibility of drugs and therapeutic quality in French-speaking Africa is a major concern of the pharmaceutical industry in France, and was discussed at a conference organized by the French drug industry association SNIP, in April 1994.
Papers presented at the conference and the ensuing debates are now available in book form. They include: new conditions of access to drugs after the devaluation; the European Development Fund medicines policy; and the setting up and management of "social" drug lists. For further details and to obtain a copy, priced 165 francs (plus 20 francs p&p) contact: SEFEFIM, 25 rue de Montevideo, 75015 Paris, France.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze